| Autor: |
Laura Robison, Yeoungjee Cho, Andrea K. Viecelli, David W. Johnson, Carmel M. Hawley, Andrea Valks, Peta-Anne Paul-Brent, Ruth Stastny, Julie Varghese, Charani Kiriwandeniya, Elaine M. Pascoe, Liza A. Vergara, Magid A. Fahim, Neil Boudville, Rathika Krishnasamy, Donna Reidlinger, on behalf of the Australasian Kidney Trials Network |
| Jazyk: |
angličtina |
| Rok vydání: |
2021 |
| Předmět: |
|
| Zdroj: |
Trials, Vol 22, Iss 1, Pp 1-9 (2021) |
| Druh dokumentu: |
article |
| ISSN: |
1745-6215 |
| DOI: |
10.1186/s13063-021-05200-0 |
| Popis: |
Abstract The unprecedented demand placed on healthcare systems from the COVID-19 pandemic has forced a reassessment of clinical trial conduct and feasibility. Consequently, the Australasian Kidney Trials Network (AKTN), an established collaborative research group known for conducting investigator-initiated global clinical trials, had to efficiently respond and adapt to the changing landscape during COVID-19. Key priorities included ensuring patient and staff safety, trial integrity and network sustainability for the kidney care community. New resources have been developed to enable a structured review and contingency plan of trial activities during the pandemic and beyond. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
